|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
167.68(B) |
Last
Volume: |
2,256,036 |
Avg
Vol: |
2,733,398 |
52
Week Range: |
$214.27 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
12,096 |
21,654 |
43,486 |
Total Sell Value |
$0 |
$3,300,412 |
$5,808,718 |
$11,189,871 |
Total People Sold |
0 |
2 |
3 |
6 |
Total Sell Transactions |
0 |
2 |
3 |
9 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Khosla Rachna |
SVP, Business Development |
|
2024-03-18 |
4 |
D |
$268.87 |
$117,765 |
D/D |
(438) |
8,190 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2024-03-18 |
4 |
D |
$268.87 |
$5,527,967 |
D/D |
(20,560) |
664,077 |
|
- |
|
Griffith Peter H. |
EVP & CFO |
|
2024-03-18 |
4 |
D |
$268.87 |
$1,389,520 |
D/D |
(5,168) |
34,710 |
|
- |
|
Gordon Murdo |
EVP, Global Commercial Ops |
|
2024-03-18 |
4 |
D |
$268.87 |
$1,737,169 |
D/D |
(6,461) |
51,321 |
|
- |
|
Reese David M |
EVP & Chief Technology Officer |
|
2024-03-18 |
4 |
D |
$268.87 |
$1,667,532 |
D/D |
(6,202) |
60,666 |
|
- |
|
Busch Matthew C. |
VP, Finance & CAO |
|
2024-03-18 |
4 |
D |
$268.87 |
$39,255 |
D/D |
(146) |
4,670 |
|
- |
|
Miller Derek |
SVP, Human Resources |
|
2024-03-18 |
4 |
D |
$268.87 |
$127,713 |
D/D |
(475) |
8,419 |
|
- |
|
Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
|
2024-03-18 |
4 |
D |
$268.87 |
$1,580,687 |
D/D |
(5,879) |
34,232 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2024-03-18 |
4 |
D |
$268.87 |
$1,650,055 |
D/D |
(6,137) |
70,213 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2024-03-18 |
4 |
D |
$268.87 |
$189,016 |
D/D |
(703) |
12,220 |
|
- |
|
Khosla Rachna |
SVP, Business Development |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,256 |
8,597 |
|
- |
|
Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,760 |
39,925 |
|
- |
|
Miller Derek |
SVP, Human Resources |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,311 |
8,863 |
|
- |
|
Busch Matthew C. |
VP, Finance & CAO |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
418 |
4,799 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,954 |
12,866 |
|
- |
|
Gordon Murdo |
EVP, Global Commercial Ops |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,924 |
57,569 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,278 |
76,125 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
41,133 |
683,910 |
|
- |
|
Reese David M |
EVP & Chief Technology Officer |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,407 |
66,653 |
|
- |
|
Griffith Peter H. |
EVP & CFO |
|
2024-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,338 |
39,250 |
|
- |
|
Bradner James E. |
EVP, R&D, & Chief Sci. Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
22,393 |
22,393 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2023-12-04 |
4 |
S |
$273.03 |
$572,276 |
D/D |
(2,096) |
10,874 |
|
-3% |
|
Reese David M |
EVP, Research and Development |
|
2023-11-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
165 |
54,164 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2023-11-08 |
4 |
S |
$272.81 |
$2,728,136 |
D/D |
(10,000) |
28,078 |
|
0% |
|
Busch Matthew C. |
VP, Finance & CAO |
|
2023-11-05 |
4 |
D |
$269.86 |
$67,195 |
D/D |
(249) |
4,367 |
|
- |
|
2150 Records found
|
|
Page 1 of 86 |
|
|